

WELCOME LETTER



Dear Friends and Colleagues,

It is with pleasure that I welcome you to Rome for the 5th International Meeting on New Drugs (and New Concepts) in Breast Cancer, bringing together clinicians, mainly medical oncologists, and researchers including this year a substantial translational research component. The issues enlisted in this preliminary program, in particular including data from clinical trials stemming from that original basic research, demonstrate how the translation of basic research into practical clinical tools is particularly active in this disease.

The program has been designed in the pursuit of excellence and, as usually, all lectures will be presented by an international distinguished outstanding faculty who will report all their experiences and developments.

I look forward to joining you and I also hope you can enjoy a unique and pleasant stay in our wonderful City.

Francesco Cognetti

WITH AN UNRESTRICTED EDUCATIONAL GRANT OF

PRINCIPAL SPONSORS

Lilly | ONCOLOGY

Roche

MAJOR SPONSORS

AstraZeneca

Celgene

MSD

NOVARTIS

Pfizer Oncology

TEVA

SPONSORS

AMGEN

Eisai

Genomic Health

IPSEN
Innovation for patient care

ISTITUTO GENTILI

ITALFARMACO

Pierre Fabre
Pharma

Takeda

CME PROVIDER

AIM Education - Provider n. 93

Via G. Ripamonti, 129 - 20141 Milan, Italy
Ph. +39 02 56601.1 - Fax +39 02 70048585
cme@aimgroup.eu - www.aimeducation.it

ORGANIZING SECRETARIAT

AIM Group International



Rome Office
Via Flaminia, 1068 - 00189 Rome
Ph. +39 06 33053.1 - Fax +39 06 33053249
breastcancer2017@aimgroup.eu
<http://web.aimgroupinternational.com/2017/breastcancer>

IRE
ISTITUTO NAZIONALE TUMORI
REGINA ELENA
ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

5th International Meeting on New Drugs (and New Concepts) in Breast Cancer

ROME, NOVEMBER 9-10, 2017

Regina Elena National Cancer Institute
Bastianelli Congress Centre

PRESIDENT: Francesco Cognetti

Under the patronage of

Aim
Associazione Italiana di Oncologia Medica

insieme contro il cancro

FACULTY



V. Adamo, Messina (Italy)

G. Arpino, Naples (Italy)

A. Bardia, Boston (USA)

G. Bianchini, Bergamo (Italy)

C. Boni, Reggio Emilia (Italy)

C. Botti, Rome (Italy)

E. Bria, Verona (Italy)

P. Bruzzi, Genoa (Italy)

R.T. Chlebowsky, Los Angeles (USA)

S. Cinieri, Brindisi (Italy)

F. Cognetti, Rome (Italy)

P. Conte, Pisa (Italy)

M. Cristofanilli, Chicago (USA)

J.P. Crown, Dublin (Ireland)

G. Curigliano, Milan (Italy)

R. Danesi, Pisa (Italy)

A. De Censi, Genoa (Italy)

M. De Laurentiis, Naples (Italy)

S. De Placido, Naples (Italy)

L. Del Mastro, Genoa (Italy)

A. Di Leo, Prato (Italy)

M.J. Duffy, Dublin (Ireland)

A. Fabi, Rome (Italy)

G. Ferretti, Rome (Italy)

R.S. Finn, Los Angeles (USA)

C. Fontanella, Aviano (Italy)

A. Gennari, Genoa (Italy)

P. Giacomini, Rome (Italy)

S. Gori, Negrar-VR (Italy)

V. Guarneri, Padua (Italy)

A. Howell, Manchester (United Kingdom)

M. Lambertini, Genoa (Italy)

C.L. Loprinzi, Rochester (USA)

V. Lorusso, Bari (Italy)

R. Masetti, Rome (Italy)

D.C. McKenzie, Vancouver (Canada)

G. Mustacchi, Trieste (Italy)

G. Naso, Rome (Italy)

C. Nisticò, Rome (Italy)

E. Perez, San Francisco (USA)

P. Pronzato, Genoa (Italy)

F. Puglisi, Udine (Italy)

L.M. Repetto, Rome (Italy)

F. Roila, Perugia (Italy)

V. Sacchini, Milan (Italy)

D. Santini, Rome (Italy)

F. Scaldaferrì, Rome (Italy)

M. Scaltriti, New York (USA)

D.B. Solit, New York (USA)

U. Tirelli, Aviano (Italy)

C. Tondini, Bergamo (Italy)

C.J. Twelves, Leeds (United Kingdom)

S. Vella, Rome (Italy)

K. Willard-Gallo, Brussels (Belgium)

THURSDAY, NOVEMBER 9



09.00 Lecture

The tumor microenvironment in breast cancer growth and progression (*A. Howell*)

1ST SESSION

HER2 POSITIVE TUMORS

Chairmen: *F. Puglisi, C. Tondini*

09.20 New biology concepts (*G. Curigliano*)

09.40 Optimizing neoadjuvant and adjuvant treatment (*G. Curigliano*)

10.00 When do you add an endocrine drug to the Her2 dual blockade? (*G. Arpino*)

10.20 Treatment duration of HER2-directed agents in metastatic disease (*E. Perez*)

10.40 Drug resistance: mechanism and clinical results (*M. Scaltriti*)

11.00 The use of biosimilars (*R. Danesi*)

11.20 Coffee Break

2ND SESSION

LUMINAL TUMORS

Chairmen: *C. Botti, S. Gori*

11.30 The intestinal microbiome (*F. Scalfarri*)

11.50 CD4/6 inhibitors: the role in the adjuvant/neoadjuvant setting (*M. Cristofanilli*)

12.10 New PI3K inhibitors (*G. Curigliano*)

3RD SESSION

TRIPLE NEGATIVE

Chairmen: *G. Mustacchi, G. Naso*

12.30 Lecture

Insights into the biology: new molecular classification for identifying immuno therapeutics targets (*K. Willard - Gallo*)

12.50 New Developments in the Treatment of advanced diseases and biomarkers evidence (*M.J. Duffy*)

13.10 Neo/adjuvant systemic therapy today (*M. Cristofanilli*)

13.30 Lunch

4TH SESSION

BRCA AND NEW OPINIONS

Chairmen: *S. Cinieri, L. Del Mastro*

Presenting: *R. Masetti*

14.00 Surgical update in patients with early disease and BRCA mutation (*V. Sacchini*)

14.20 Novel drugs and new trials in BRCA mutated patients (*J. Crown*)

14.40 Fertility and BRCA mutation (*M. Lambertini*)

5TH SESSION

IMMUNOSYSTEM AND IMMUNOTHERAPY

Chairmen: *E. Bria, S. De Placido*

15.00 Lecture

Immunotherapy: what we still need to know? (*E. Perez*)

15.20 New immunotargets in breast cancer (*G. Bianchini*)

15.40 The combination with nanoparticle molecules (*M. De Laurentiis*)

16.00 Discussion

6TH SESSION

NEW CONCEPTS

Chairmen: *C. Boni, E. Bria*

16.10 From phase I-III to new clinical trials methodologies in breast cancer (*P. Bruzzi*)

16.30 Trials on druggable mutations, regulatory implications (*S. Vella*)

Presenting: *P. Giacomini*

16.50 Lecture

Precision medicine in breast cancer today (*D.B. Solit*)

17.10 Discussion

FRIDAY, NOVEMBER 10



Presenting: *F. Cognetti*

Lecture

09.00 Breast cancer chemo-prevention (*A. De Censi*)

7TH SESSION

SUPPORTIVE CARE AND LIFESTYLE

Chairmen: *V. Adamo, C. Nisticò, F. Roila*

09.20 Toxicity induced by therapy: the new profile of the oncologist (*D. Santini*)

09.40 Musculoskeletal symptoms induced by aromatase inhibitors: new therapeutic approach (*C.L. Loprinzi*)

10.00 Low-fat diet: is it really a predictor for the best outcome? (*R.T. Chlebowsky*)

10.20 Physical exercise and breast cancer: risk correlation to subtype and therapeutic effect (*D.C. McKenzie*)

Presenting: *P. Pronzato*

10.40 Lecture

Adjuvant therapy in HER2 positive early breast cancer: for whom? How long? With what? (*P.F. Conte*)

11.00 Coffee Break

8TH SESSION

EVOLVING MOLECULES

Chairmen: *G. Ferretti, V. Guarneri*

11.10 Etirinotecal pegol: in which position in the future clinical choice? (*C.J. Twelves*)

11.30 Trop-2: potential target for antibody-drug conjugates (*A. Bardia*)

9TH SESSION

HORMONAL THERAPY AND NOVEL DISCOVERIES IN DRUG RESISTANCES

Chairmen: *A. Fabi, V. Lorusso*

11.50 Lecture

Mechanism and clinical results in ER positive patients (*A. Di Leo*)

12.10 New selective estrogen receptor antagonist (*R.S. Finn*)

12.30 Lecture

Clinical utility of multigene assays and outcome of disease (*M. De Laurentiis*)

10TH SESSION

AGE AND BREAST CANCER

Chairmen: *A. Gennari, U. Tirelli*

12.50 Evaluation and treatment of older patients (in early stage) (*L.M. Repetto*)

13.10 The treatment of Metastatic disease in elderly patients, light and shadow (*C. Fontanella*)

13.30 Discussion and Conclusions

14.00 Lunch

SCIENTIFIC COMMITTEE

P. Conte (Padua, I)

M. De Laurentiis (Naples, I)

S. De Placido (Naples, I)

L. Del Mastro (Genoa, I)

A. Di Leo (Prato, I)

S. Gori (Negrar-VR, I)

P. Pronzato (Genoa, I)

LOCAL SCIENTIFIC COORDINATORS

Alessandra Fabi

LOCAL SCIENTIFIC COMMITTEE

Daniele Alesini

Simona Gasparro

Paola Malaguti

CONGRESS VENUE AND GENERAL INFORMATION

Meeting Venue

Regina Elena National Cancer Institute – Raffaele Bastianelli Congress Centre
Via Fermo Ognibene, 23 – 00144 Rome

Language

The official language of the Congress is English. Simultaneous translation will not be provided.

Certificate of attendance

Certificates will be issued to all registered participants who will expressly make request at the Secretariat Desk at the end of the Congress.

ECM - Educazione Continua in medicina - for Italian delegates only

L'evento è stato accreditato presso la Commissione Nazionale per la Formazione Continua con Obiettivo Formativo di Processo: integrazione interprofessionale e multiprofessionale, interistituzionale (8) per la Figura Professionale FARMACISTA con specializzazione nelle seguenti discipline FARMACIA OSPEDALIERA; FARMACIA TERRITORIALE; per la Figura Professionale BIOLOGO con specializzazione nelle seguenti discipline BIOLOGO; per la Figura Professionale MEDICO CHIRURGO con specializzazione nelle seguenti discipline ONCOLOGIA; RADIOTERAPIA; CHIRURGIA GENERALE; CHIRURGIA PLASTICA E RICOSTRUTTIVA; ANATOMIA PATOLOGICA; RADIODIAGNOSTICA; MEDICINA GENERALE (MEDICI DI FAMIGLIA); per un numero massimo di n. 200 partecipanti. Oltre tale numero e per professioni/discipline differenti da quelle accreditate non sarà possibile rilasciare i crediti formativi. Si precisa che i crediti verranno erogati a fronte di una partecipazione del 90% ai lavori scientifici e del superamento della prova di apprendimento con almeno il 75% delle risposte corrette. L'EVENTO HA OTTENUTO NR. 8,4 CREDITI FORMATIVI – **ID ECM: 93-204540 - ED.1**

REGISTRATION INFORMATION

· Registration Fee	€ 183,00 (VAT 22% included)
· Registration for doctors of Regina Elena National Cancer Institute	FREE
· Post graduate students	FREE

The registration fee entitles delegates to the following:

- entry to scientific sessions
- 1 coffee break and 1 buffet lunch on November 9 and 10, 2017
- CME credits
- congress material
- certificate of attendance